HC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS)

HC Wainwright reiterated their buy rating on shares of COMPASS Pathways (NASDAQ:CMPS - Free Report) in a research note published on Tuesday,Benzinga reports. HC Wainwright currently has a $45.00 price target on the stock. HC Wainwright also issued estimates for COMPASS Pathways' Q2 2025 earnings at ($0.38) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.55) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($1.62) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at $0.04 EPS and FY2029 earnings at $1.59 EPS.

Several other research firms have also issued reports on CMPS. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $12.00 price target on shares of COMPASS Pathways in a report on Tuesday, May 27th. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 price target (down from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, COMPASS Pathways has an average rating of "Moderate Buy" and a consensus price target of $17.00.

COMPASS Pathways Stock Up 10.8%

NASDAQ CMPS traded up $0.42 on Tuesday, hitting $4.30. The stock had a trading volume of 4,573,064 shares, compared to its average volume of 1,301,990. The business's fifty day moving average price is $3.94 and its 200 day moving average price is $3.77. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.18 and a quick ratio of 10.18. COMPASS Pathways has a 52-week low of $2.25 and a 52-week high of $8.54. The stock has a market cap of $402.31 million, a price-to-earnings ratio of -2.16 and a beta of 2.12.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.03. Equities research analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CMPS. RTW Investments LP acquired a new position in COMPASS Pathways during the fourth quarter valued at $11,714,000. Nantahala Capital Management LLC raised its position in shares of COMPASS Pathways by 182.9% in the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company's stock worth $8,092,000 after acquiring an additional 1,829,232 shares during the period. Vivo Capital LLC boosted its stake in shares of COMPASS Pathways by 109.1% during the 1st quarter. Vivo Capital LLC now owns 3,362,385 shares of the company's stock worth $9,616,000 after acquiring an additional 1,754,385 shares in the last quarter. Altium Capital Management LLC purchased a new stake in shares of COMPASS Pathways during the 4th quarter worth about $5,384,000. Finally, Woodline Partners LP boosted its stake in shares of COMPASS Pathways by 279.9% during the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company's stock worth $5,019,000 after acquiring an additional 1,292,927 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.